Abstract Body

Background

Physiologic changes that occur during pregnancy can significantly alter the pharmacokinetics (PK) of antiretrovirals (ARV), potentially impacting maternal HIV suppression and vertical transmission risk.  Doravirine (DOR), a once-daily potent NNRTI with a strong safety profile, could be used during pregnancy if data were available to optimize dosing strategies during gestation and post-partum.    

Methods

This was a single-center, phase IV, single dose (SD), longitudinal study in pregnant women living with HIV (NCT04900974/IND151534). Women enrolled if they were adherent to ARVs with an undetectable HIV RNA.  Intensive SD 72hr PK profiles of DOR 100mg were performed during the 2nd (20-26wk) and 3rd (30-34wk) trimester and postpartum (4-8wk).  Total and protein-unbound DOR concentrations were measured by validated LC-MS/MS methods at limits of 3 and 0.3ng/mL, respectively.  Noncompartmental PK parameters were calculated using Phoenix WinNonlin v8.6; comparisons were made using Friedman’s and post hoc Wilcoxon signed-rank with Bonferroni adjustment.  Data are presented as median(range). 

Results

8 subjects were screened, 7 enrolled and 5 (1 white, 3 Hispanic, 1 Black) aged 28 (21-30)yrs with a BMI of 37 (26-49)kg/m2 completed the study. Of those completing, 4 were prescribed TAF/FTC/BIC, and 1 was taking TDF/FTC/DTG. No AEs were noted. Albumin declined to a low of 2.6 (2.3-3.1) in the 3rd trimester, but no consistent or significant DOR protein binding changes were noted.  SD PK parameters are summarized in the table.  Friedman’s noted statistically significant differences in C24h, however no significant differences were found with post-hoc analysis. Steady-state (SS) C24h estimates are in the table, calculated using an accumulation ratio of 1.38, derived from SD terminal elimination rates.    

Conclusions

SD PK data of DOR were collected safely from pregnant women to identify pregnancy-induced changes.  Significant differences were noted in total and unbound C24h. While calculated SS C24h concentrations are within previously identified effective concentration ranges (PMCID6437494), it would be prudent to closely monitor HIV RNA in pregnant women until more clinical data (NTC05630638) are available.  

Table or Figure